Figure 1.

Flow chart of patient selection. Of the 135 patients who provided informed consent, 35 were excluded because they did not meet the inclusion criteria, etc., and the remaining 100 were temporarily registered. Twenty‐three patients were further excluded, leaving 77 for final registration at baseline (Week 0). Seventy‐four patients (37 each) completed the study. Elo, Elobixibat group; Pbo, Placebo group.